APA (7th ed.) Citation

HN, L., P, H., A, W., K, Ś., N, S., D, V., . . . RL, L. (2026). Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: Unadjusted and adjusted indirect comparisons. Frontiers in oncology, 15, 1736165. https://doi.org/10.3389/fonc.2025.1736165

Chicago Style (17th ed.) Citation

HN, Lode, et al. "Dinutuximab Beta Versus Historical Controls in the Treatment of Relapsed Neuroblastoma: Unadjusted and Adjusted Indirect Comparisons." Frontiers in Oncology 15 (2026): 1736165. https://doi.org/10.3389/fonc.2025.1736165.

MLA (9th ed.) Citation

HN, Lode, et al. "Dinutuximab Beta Versus Historical Controls in the Treatment of Relapsed Neuroblastoma: Unadjusted and Adjusted Indirect Comparisons." Frontiers in Oncology, vol. 15, 2026, p. 1736165, https://doi.org/10.3389/fonc.2025.1736165.